Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program

Registration is complimentary for ISOPP members. Join here now for no-fee: https://www.isopp.org/member-benefits

How to acess: Once logged on as member, click on e-learning in the top purple banner to access the ISOPP e-learning platform and this course. 

Recognizing that there is a rapid expansion of Biosimilars usage in clinical practice, and that the role of an oncology pharmacist is evolving and further integrating as a key member of a multidisciplinary healthcare team, ISOPP developed the Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) online education program that supports oncology pharmacists to safely and confidently introduce Biosimilars into their clinical practice and multidisciplinary healthcare team.

ISOPP presents this education program in a novel way by giving both fundamentals and advanced aspects of 1) pharmacotherapy of various cancers, 2) implementation of biosimilars in oncology practice and 3) interpretation of available scientific and regulatory data and pharmacist’s recommendations for using biosimilars in different cancers.

The Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program is supported by Pfizer through an educational grant.

The program launched in October 2021 and consists of 10 online courses (total of 25 hours), supplemented by a Biosimilars Masterclass, which took place at ISOPP’s 2023 Symposium in Spain. You can now access the 10 online modules as part of your ISOPP membership. 

 

We acknowledge the Faculty members, Reviewers and Task Force members for their contributions to the OPAB Program.

 

 

This program is supported by an educational grant from Pfizer.

 

Please note that these modules were authored in 2020/2021 and may contain elements of practice that have now been superseded. ISOPP cannot accept responsibility for any errors or omissions or for any consequences from application of information in the course and make no warranty, expressed or implicit with respect to the contents of this course. You must consider professional or specialist advice before taking, or refraining from, any action on the basis of the content of the course or document(s) downloaded